Skip to main content

March 2015, Vol 8, Sixth Annual Payers' Guide

Payers' Guide, FDA Approvals

Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis

Payers' Guide, FDA Approvals

Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis

Payers' Guide, FDA Approvals

Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin- Structure Infections

Payers' Guide, FDA Approvals

Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Page 2 of 3
Results 11 - 20 of 27